Daien C, Krogulec M, Gineste P, Steens JM, et al. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study. Ann Rheum Dis 2022 May 31. pii: annrheumdis-2022-222228.
PMID: 35641124